Cellyan Biotechnology (HKPD) Liabilities and Shareholders Equity (2024 - 2025)
Cellyan Biotechnology (HKPD) reported Liabilities and Shareholders Equity of $9.6 million for Q3 2025, down 5.2% year-over-year from $10.2 million in Q3 2024, and up 2.3% quarter-over-quarter from $9.4 million in Q1 2025.
Cellyan Biotechnology (HKPD) Liabilities and Shareholders Equity (2024 - 2025) Analysis & Trends
Cellyan Biotechnology (HKPD) has 2 years of Liabilities and Shareholders Equity data on file, last reported at $9.6 million in Q3 2025.
- Liabilities and Shareholders Equity for Q3 2025 came in at $9.6 million, down 5.2% year-over-year; the trailing twelve-month figure through Sep 2025 was $37.9 million (changed N/A YoY), and the FY2025 annual result was $9.4 million, up 8.65% from the prior year.
- Liabilities and Shareholders Equity grew to $9.6 million in Q3 2025 per HKPD's latest filing, from $9.4 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $10.2 million in Q3 2024 and troughed at $8.7 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Akso Health | 2,315,158.81 Bn | 2,315,158.63 Bn | - | 212.04 Mn |
| 2 | Mckesson | 92.76 Bn | 89.18 Bn | 4.04 Bn | 82.32 Bn |
| 3 | Cencora | 52.82 Bn | 50.83 Bn | 3.59 Bn | 81.65 Bn |
| 4 | Cardinal Health | 52.17 Bn | 48.39 Bn | 2.50 Bn | 56.69 Bn |
| 5 | Henry Schein | 9.19 Bn | 9.71 Bn | 1.07 Bn | 11.30 Bn |
| 6 | Accendra Health | 246.88 Mn | -90.00 Mn | 312.39 Mn | 2.42 Bn |
| 7 | Edap Tms | 161.92 Mn | 146.92 Mn | 8.15 Mn | 72.06 Mn |
| 8 | 111 | 107.47 Mn | 25.61 Mn | 23.58 Mn | 310.22 Mn |
| 9 | Cosmos Health | 9.42 Mn | 7.26 Mn | 1.38 Mn | 62.37 Mn |
| 10 | Cellyan Biotechnology | 5.69 | -2.48 Mn | - | 9.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 9.63 Mn |
| Mar 31, 2025 | 9.42 Mn |
| Sep 30, 2024 | 10.16 Mn |
| Mar 31, 2024 | 8.67 Mn |